Biomarcadores. orientação terapêutica
|
|
- Julianna Chandler
- 5 years ago
- Views:
Transcription
1 Biomarcadores estratificação do risco e orientação terapêutica Pedro Póvoa Faculdade de Ciências Médicas Universidade Nova de Lisboa Unidade de Cuidados Intensivos Médicos Hospital de São Francisco Xavier Centro Hospitalar de Lisboa Ocidental 14º Simpósio de Infecção e Sepsis 1 a 3 de Abril de 2009 Porto
2 Biomarkers risk stratification and treatment guidance Pedro Póvoa Professor of Medicine Medical Sciences Faculty New University of Lisbon Medical Intensive Care Unit São Francisco Xavier Hospital 14º Simpósio de Infecção e Sepsis 1 a 3 de Abril de 2009 Porto
3 Biomarkers Sepsis Risk stratification Treatment guidance
4 Risk stratification & Cancer TNM staging (Denoix, 40s) is a descriptor of how much the cancer has spread T size or direct extent of the primary tumor N degree of spread to regional lymph nodes M presence of metastasis Correct staging is critical: Prognosis Treatment (related to disease stage) Hermanek Cancer 1999;86:2189
5 ACCP/SCCM Consensus Conference SIRS; 2 criteria temperature >38 C or <36 C tachycardia >90 beats/min tachypnea >20 breaths/min or PaCO2 < 32 mmhg leucocytosis >12.000/mL, leucopenia <4.000/mL or >10% band cells Sepsis SIRS that has a proven or suspected microbial etiology Severe Sepsis Sepsis with signs of organ dysfunction, hypoperfusion or hypotension; hypoperfusion includes lactic acidosis, oliguria and altered mental state Septic Shock sepsis induced hypotension despite adequate fluid resuscitation CCM 1992;20:864
6 3768 pts 3 ICU, 3 wards Sepsis 649 (26%) SIRS 2527 (68%) Severe Sepsis 467 (18%) Septic Shock 110 (4%) Mort tality (%) (44%) Previously classified as SIRS 271 (58%) Previously classified as SIRS or sepsis 78 (71%) Previously classified as SIRS, sepsis or Severe sepsis 0 3 No SIRS SIRS2 SIRS3 SIRS4 Sepsis Severe Sepsis Septic Shock Continuum from SIRS to sepsis to severe sepsis to septic shock Rangel-Frausto JAMA 1995;273:117
7 Markers provide information in one or more of three domains: diagnosis, prognosis, and response to therapy (>80 putative markers of sepsis). All correlate with the risk of mortality (prognosis), yet none has shown utility in stratifying patients with respect to therapy (diagnosis) or in titrating that therapy (response). Their limitations arise from the challenges of establishing causality in a complex disease process such as sepsis and of stratifying patients into more homogeneous populations. The latter suggests the need for a staging system analogous to those used in other complex disease processes such as cancer. A candidate framework for such a system, based on the infection, the host response, and the extent of organ dysfunction (the IRO system) Marshall J Crit Care Med 2003; 31:1560
8 IRO system - staging Stage I presence of the insult (infection) with only a modest (or absent) response and no organ dysfunction: I1R1O0. Such a population might be appropriate for trials of a new antibiotic. Stage II presence of the insult with modest response and organ dysfunction of the primary site of infection or the presence of inflammation of unknown origin with moderate response and absent organ dysfunction: I1 (acute lung injury) R1 (inflammatory-induced injury) O1 (organ dysfunction limited to the respiratory system) could be used to designed a study to prevent ventilator-induced lung injury and its sequelae Stage III presence of an insult with severe response and a moderate organ dysfunction: Ix (inflammation, cause not specified) R2 (evidence of microvascular thrombosis; for example, elevated D-dimers) and O1 (organ dysfunction compatible with microvascular ischemia involving two or more organ systems) could be used to study an anticoagulant. Stage IV presence of an insult with severe response and organ dysfunction: Ix (inflammation, cause not specified) R3 (biochemical evidence of marked systemic inflammation) and O2 (established organ dysfunction necessitating extracorporeal support) could be designed to study a salvage therapy such as plasmapheresis. Marshall J et al. Crit Care Med 2003; 31:1560
9 1. Current concepts of sepsis, severe sepsis and septic shock remain useful 2. These definitions do not allow precise staging or prognostication of the host response to infection 3. SIRS remains an useful concept (although overly sensitive and non-specific) 4. An expanded list of signs and symptoms of sepsis may better reflect the clinical response to infection 5. PIRO, a hypothetical model for staging sepsis is presented, which, in the future, may better characterize the syndrome on the basis of 1. Predisposing factors and premorbid conditions, 2. the nature of the underlying Insult (Infection) 3. the characteristics of the host Response 4. the extent of the resultant Organ dysfunction
10 PIRO system/stratification optimum individualized treatment Predisposition Genetic susceptibility Coexisting health complications Insult (Infection) Pathogen, toxicity and sensitivity Location and compartmentalization Biomarkers in Sepsis Can we use them in risk stratification? Response Increased biomarkers or biomediators Manifested physiologic symptoms Organ Dysfunction Number of failing organs Carrigan Clin Chem 2004;50:1301
11 Predisposition Preinfection risk of CAP N=3075 (70-79 yrs) 161 CAP Follow-up 6.5 yrs TNF, IL6, CRP (inclusion) TNF >3.7 pg/ml AOR 1.6 (95%CI, ) IL6 >2.4 pg/ml AOR 1.7 (95%CI, ) No comorbidities biomarkers, no risk Comorbibities biomarkers, risk Yende AJRCCM 2005;172:1440
12 Insult Biomarkers and Diagnosis of Infection Sensitivity (%) Specificity (%) AUC PCT CRP Simon CID 2004;39:206. Erratum: CID 2005;40:1386 van der Meer BMJ 2005;331:26 Uzzan CCM 2006;34:1996 Tang Lancet Infect Dis 2007;7:210 PROBLEMS 1. ACCP/SCCM Consensus Conference criteria to define the presence or absence of sepsis (assessing degrees of clinical severity) 2. Gold standard, that is presence of documented infection versus no infection and no antibiotic therapy (Cohen CCM 2001;29:880) Póvoa Curr Opin Infect Dis 2008;21:157
13 PANEL OF BIOMARKERS Prospective N=1800 Multiplex technology: xmap AUC for bacterial cause of SIRS: supar 0.50 strem MIF 0.63 PCT 0.72 neutrophil count 0.74 CRP (95% CI 0.71 to 0.91) for the composite three-marker test 0.88 (95% CI 0.81 to 0.92) for the composite six-marker test Increases costs More time consuming Interpretation? Kofoed Clin Chem 2006;52:1284 Kofoed Critical Care 2007;11:R38
14 Fast PCR pathogen detection DNA fingerprinting
15 Fast PCR pathogen detection
16 Biomarkers of infection Single determination value in the diagnosis of infection Serial determinations as predictor of infection monitoring clinical course and response to antibiotic therapy Póvoa ICM 2002;28:235 Póvoa Curr Opin Infect Dis 2008;21:157
17 CRP controls and infected day -5 to day 0 N=63 pts (28 controls; 35 infected documentation) p< ,00,75,50 days sensibilidade sensitivity,25 0,00 0,00 Max daily CPR AUC (day -5 to day 0) 0.86 (95% CI: ),25 1-specificity 1 - especificidade,50,75 1,00 maximum daily CRP > 4.1 mg/dl infection sensitivity 0.92, specificity 0.71, LR+ 3.22, LR Póvoa Critical Care 2006;10:R63
18 PCT with and without VAP D-5 to D1 N=73 pts (32 with and 41 without VAP) BAL diagnosis 1 with Sensiti ivity without PCT Increase PCT Specificity PCT kinetics low diagnostic accuracy for VAP Luyt C et al. ICM 2008;34:1434
19 Response simplified hypothetical host response to infection sample SIRS steroids monoclonal Ab rhapc CARS immunonutrition INF - γ CSF plasmafiltration... Immune Monitoring: Can we assess the immune status to design an intervention? Hotchkiss NEJM 2003;348:138
20 22 RCT Macias Critical Care 2005; 9:R607
21 Anti-inflammatory therapies in sepsis Macias Critical Care 2005; 9:R607
22 Panels of Biomarkers 60 septic pts (mortality 48.3%) 17 cytokines (IL1β, IL2, IL4, IL5, IL6, IL7, IL8, IL10, IL12, IL13, IL17, INFγ, G-CSF, GM-CSF, MCP-1, MIP-1, TNFα) Multiplex cytokine kit 1020 measurements 310 (30.4%) undetectable Organ dysfunction (SOFA) IL8, MCP-1 Mortality (small differences) IL1β, IL4, IL6, IL8, MCP-1, G-CSF Severe sepsis (N=14) Septic shock (N=46) IL1β IL IL <0.001 IL IL <0.001 IL INFγ MCP <0.001 TNFα <0.001 pg/ml p Bozza Critical Care 2007;11:R49
23 Genomics and sepsis Tang CCM 2009;37:882
24
25
26 Organ dysfunction TNM system/sepsis analogy (Presence of metastasis organ dysfunction) Cancer Metastatic disease influences treatment and prognosis Sepsis Organ dysfunction influences prognosis; treatment?
27 Organ dysfunction Severity of sepsis & Biomarkers PCT Data from 12 published papers CRP N=158 septic pts (76 documented) r s = 0.18; r 2 s = 0.03; p=0.035 Carrigan Clin Chem 2004;50:1301 Silvestre J et al. ICM 2009 (in press)
28 Organ Dysfunction Biomarkers N=150 ICU pts N=158 septic pts (76 documented) Castelli Minerva Anestesiol 2006;72:69 Silvestre J et al. ICM 2009 (in press)
29 PIRO stratification VAP PIRO, N=441 (Lisboa T Chest 2008;134:1208) P Comorbidities, I bacteremia, R systolic BP < 90 mm Hg, O ARDS (score range: 0-4) simple, clinical tool for VAP stratification and predicting ICU mortality (AUC VAP PIRO 0.81 >> APACHE II 0.53) CAP PIRO, N=529 (Rello J CCM 2009 ahead of print) P Comorbidities, age >70 years, I bacteremia, multilobar opacities in x-ray, R shock, severe hypoxemia, O ARDS, acute renal failure (score range: 0-8) simple, clinical tool for CAP stratification and predicting ICU mortality (AUC CAP PIRO 0.88 > IDSA/ATS criteria 0.8, APACHE II 0.75) SAPS 3 PIRO, N=2628 (Moreno R ICM 2008;34:496) P age, location from which the patient was admitted to the ICU, comorbidities, length of stay before ICU admission, reasons for ICU admission, I acquisition of infection, extension of infection, site of infection, and infective agent, R organ dysfunction/failure (score range: 0-114) complex (additional calculations), clinical tool of septic patients stratification and predicting ICU mortality (AUC SAPS 3 PIRO > SAPS )
30 PIRO staging system NO USE OF BIOMARKERS!
31 Biomarkers Sepsis Risk stratification Treatment guidance procalcitonin
32 Procalcitonin ProRESP study 243 pts with suspected LRTI Standard, N = 119 PCT guided, N = 124 PCT guided group 0.1µg/l no infection no AB µg/l infection unlikely no AB µg/l possible infection AB > 0.5µg/l infection AB Re-evaluation 6-24h after admission Christ-Crain Lancet 2004;363:600
33 Procalcitonin Christ-Crain Lancet 2004;363:600
34 Procalcitonin ProCAP study 302 pts suspected of CAP AB based on PCT: < 0.1µg/l strongly discouraged µg/l discouraged µg/l encouraged > 0.5µg/l strongly encouraged Re-evaluation 6-24h after admission Primary end point - AB use Outcome: PCT vs standard Cured 85% vs 85% (p=.65) Mortality 12% vs 13% (p=.73) Christ-Crain AJRCCM 2006;174:84
35 Procalcitonin ProCOLD study 208 AECB Primary outcome AB exposure Subsequent AB 6 months PCT group (N=102); Standard (N=106) AB based on PCT ( criteria!): 0.1µg/l no infection µg/l possible infection > 0.25 µg/l bacterial infection Re-evaluation 6-24h after admission PCT vs standard (6 months) Hospitalization 17.7 vs 20.8 (p=.5) Mortality 4.9 vs 8.5 (p=.4) Stolz Chest 2007;131:9
36 Procalcitonin antibiotic stewardship ICU setting N=79 (69% respiratory) (39 PCT-guided; 40 control) 203 (72%) pts excluded! PCT-guided stop AB if D1 PCT 1 µg/l reevaluated D5 1) PCT >90% 2) PCT < 0.25 µg/l D1 PCT < 1 µg/l (at least 3d AB) 1) PCT < 0.1 µg/l positive blood cultures at least 5 days AB Mortality (PCT-guided 20.5%;control 20%) Intention to treat analysis - NS PCT-guided AB <4-day in the duration of antibiotic therapy (p=0.003) (N=25!) smaller antibiotic exposure (p=0.0002) <2-day ICU stay (p=0.03) Nobre AJRCCM 2008;177:498
37 Can Biomarkers be useful in risk stratification and treatment guidance? YES! YES!
38
Sepsis the clinical syndrome
Sepsis the clinical syndrome João Gonçalves Pereira ICU director Vila Franca Xira Hospital Systemic Inflamatory Response 2 Temperature 38ºC or 36ºC bacteraemia other trauma HR 90/min INFECTION RR 20/min
More informationUsefulness of Procalcitonin in the management of Infections in ICU. P Damas CHU Sart Tilman Liège
Usefulness of Procalcitonin in the management of Infections in ICU P Damas CHU Sart Tilman Liège Procalcitonin Peptide 116 AA Produced by parenchymal cells during «sepsis»: IL1, TNF, IL6 : stimulators
More informationFluorescence immunoassay Point of care test Wide range PCT. whole blood. plasma. serum
Fluorescence immunoassay Point of care test Wide range PCT whole blood serum plasma ichroma PCT Description ichroma PCT along with ichroma Reader is a fluorescence immunoassay for quantitative determination
More informationUse of surrogate inflammatory markers in the diagnosis & monitoring of patients with severe sepsis
Thursday 11 th June 2015 Use of surrogate inflammatory markers in the diagnosis & monitoring of patients with severe sepsis Dr Duncan Wyncoll Guy s & St Thomas NHS Trust, London Conflicts of Interest In
More informationBiomarkers for streamlining of Antibiotics in patients with severe infection.
Biomarkers for streamlining of Antibiotics in patients with severe infection. Philipp Schuetz, MD Feb, 2013 Email: Schuetzph@gmail.com You see this patient in your ICU -3d: Cough, Dyspnoe, Sputum T: 38.8
More informationSepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment
Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus
More informationVAP in COPD patients. Ignacio Martin-Loeches. St James s University Hospital. Trinity Centre for Health Sciences. Dublin Ireland.
VAP in COPD patients Ignacio Martin-Loeches St James s University Hospital. Trinity Centre for Health Sciences. Dublin Ireland. Outline Pathophysiology Is enough information? COPD trends in ICU How do
More informationR2R: Severe sepsis/septic shock. Surat Tongyoo Critical care medicine Siriraj Hospital
R2R: Severe sepsis/septic shock Surat Tongyoo Critical care medicine Siriraj Hospital Diagnostic criteria ACCP/SCCM consensus conference 1991 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
More informationProcalcitonin kinetics guided antibiotic management of the critically ill patient
Procalcitonin kinetics guided antibiotic management of the critically ill patient András LOVAS MD, PhD, EDIC, EDAIC University of Szeged, Hungary Department of Anaesthesiology and Intensive Therapy 19/11/2016,
More informationPCT. PCT in Bacterial Infections and Sepsis. Early Diagnosis. Assessment of Severity and Prognosis. Support for Therapeutic Decision Making
PCT PCT in Bacterial Infections and Sepsis Early Diagnosis Assessment of Severity and Prognosis Support for Therapeutic Decision Making Diagnosis and monitoring of sepsis Clinical need for earlier detection
More informationCurrent State of Pediatric Sepsis. Jason Clayton, MD PhD Pediatric Critical Care 9/19/2018
Current State of Pediatric Sepsis Jason Clayton, MD PhD Pediatric Critical Care 9/19/2018 Objectives Review the history of pediatric sepsis Review the current definition of pediatric sepsis Review triage
More informationSHOULD THERAPEUTIC AGENTS FOR SEPSIS TARGET THE GLYCOCALYX?
SHOULD THERAPEUTIC AGENTS FOR SEPSIS TARGET THE GLYCOCALYX? Sir Ganga Ram Hospital New Delhi, India Dr. Seema Bhargava Senior Consultant & Chairperson Department of Biochemistry & Professor, GRIPMER Sir
More informationADVANCES IN BIOMARKER TESTING FOR SEPSIS AND BACTERIAL INFECTIONS
ADVANCES IN BIOMARKER TESTING FOR SEPSIS AND BACTERIAL INFECTIONS ERIC H GLUCK MD JD FCCP FCCM DIRECTOR OF CRITICAL SERVICES SWEDISH COVENANT HOSPTIAL DISCLOSURES: Speaking engagements and consulting:
More informationDiagnosis and Management of Sepsis and Septic Shock. Martin D. Black MD Concord Pulmonary Medicine Concord, New Hampshire
Diagnosis and Management of Sepsis and Septic Shock Martin D. Black MD Concord Pulmonary Medicine Concord, New Hampshire Financial: none Disclosures Objectives: Identify physiologic principles of septic
More informationPCT-assisted antibiotic therapy
PCT-assisted antibiotic therapy Prof. Zsolt Molnár zsoltmolna@gmail.com Department of Anaesthesia and Intensive Care University of Szeged Hungary Problems with the definition of sepsis Definitive diagnoses
More informationThe Usefulness of Sepsis Biomarkers. Dr Vineya Rai Department of Anesthesiology University of Malaya
The Usefulness of Sepsis Biomarkers Dr Vineya Rai Department of Anesthesiology University of Malaya 1 What is Sepsis? Whole Body Inflammatory State + Infection 2 Incidence and Burden of Sepsis in US In
More informationKey Points. Angus DC: Crit Care Med 29:1303, 2001
Sepsis Key Points Sepsis is the combination of a known or suspected infection and an accompanying systemic inflammatory response (SIRS) Severe sepsis is sepsis with acute dysfunction of one or more organ
More informationBiomarkers in sepsis: Utility in critical care
Biomarkers in sepsis: Utility in critical care Fathima Paruk, PhD Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand Kumar A et al, Chest 2009; 136:1237-48. von Gunten et al
More informationBiomarkers in sepsis. Dr S Omar University of Witwatersrand CHBAH Bara ICU
Biomarkers in sepsis Dr S Omar University of Witwatersrand CHBAH Bara ICU Procalcitonin PCT biomarker 1993- described as a sepsis associated protein Identical to the precursor protein of calcitonin which
More informationJohn Park, MD Assistant Professor of Medicine
John Park, MD Assistant Professor of Medicine Faculty photo will be placed here park.john@mayo.edu 2015 MFMER 3543652-1 Sepsis Out with the Old, In with the New Mayo School of Continuous Professional Development
More informationSepsis is an important issue. Clinician s decision-making capability. Guideline recommendations
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012 Clinicians decision-making capability Guideline recommendations Sepsis is an important issue 8.7%
More informationPCT-assisted antibiotic therapy
PCT-assisted antibiotic therapy Prof. Zsolt Molnár zsoltmolna@gmail.com Department of Anaesthesia and Intensive Care University of Szeged Hungary Problems with the definition of sepsis Sepsis is not a
More informationDiagnostic role of soluble triggering receptor expressed on myeloid cell-1 in patients with sepsis
190 Wang et al Original Article Diagnostic role of soluble triggering receptor expressed on myeloid cell-1 in patients with sepsis Hong-xia Wang, Bing Chen Department of Emergency Medicine, Second Hospital
More informationImportance of kinetics of procalcitonin in septic patients. János Fazakas MD, PhD Semmelweis University, Department of Transplantation and Surgery
Importance of kinetics of procalcitonin in septic patients János Fazakas MD, PhD Semmelweis University, Department of Transplantation and Surgery Host pathogen interactions the innate and the adaptive
More informationHerpes virus reactivation in the ICU. M. Ieven BVIKM
Herpes virus reactivation in the ICU M. Ieven BVIKM 07.04.2011 Introduction: Viruses identified in critically ill ICU patients Viral diseases have recently been the subject of numerous investigations in
More informationNo conflicts of interest to disclose
No conflicts of interest to disclose Introduction Epidemiology Surviving sepsis guidelines 2012 Updates Resuscitation protocols Map Goals Transfusion Sepsis-3 Bundle Management Questions Sepsis is a systemic,
More informationIDENTIFYING SEPSIS IN THE PREHOSPITAL SETTING
IDENTIFYING SEPSIS IN THE PREHOSPITAL SETTING Christopher Hunter, MD, PhD, FACEP Director, Health Services Department Associate Medical Director, Orange County EMS System Medical Director, Orlando Health
More informationText-based Document. Implications of the Sepsis-3 Definition on Nursing Research and Practice. Authors Peach, Brian C. Downloaded 5-Jul :03:48
The Henderson Repository is a free resource of the Honor Society of Nursing, Sigma Theta Tau International. It is dedicated to the dissemination of nursing research, researchrelated, and evidence-based
More informationStaging Sepsis for the Emergency Department: Physician
Staging Sepsis for the Emergency Department: Physician Sepsis Continuum 1 Sepsis Continuum SIRS = 2 or more clinical criteria, resulting in Systemic Inflammatory Response Syndrome Sepsis = SIRS + proven/suspected
More informationDIAGNOSIS AND INVESTIGATIONS FOR SEPSIS. B. Mrara
DIAGNOSIS AND INVESTIGATIONS FOR SEPSIS B. Mrara CH C.H. Baragwanath ICU OUTLINE Introduction Diagnostic issues in sepsis Diagnosis and investigations for sepsis: clinical and laboratory lb investigations
More informationSession: How to manage and prevent the different faces of pneumonia Severe CAP
Athens 19, 20 November 2015 Garyfallia Poulakou Consultant, Infectious Diseases 4 th Department of Internal Medicine, Attikon University Hospital of Athens Session: How to manage and prevent the different
More informationSepsis Learning Collaborative: Sepsis New Definitions
Sepsis Learning Collaborative: Sepsis New Definitions Sepsis 3, a New Definition Todd L. Slesinger, MD, FACEP, FCCM, FCCP, FAAEM Program Director and Academic Chair Department of Emergency Medicine Disclosures
More informationBIOMARKERS IN SEPSIS: DO THEY REALLY GUIDE US? Asist. Prof. M.D. Mehmet Akif KARAMERCAN Gazi University School of Medicine Depertment of Emergency
BIOMARKERS IN SEPSIS: DO THEY REALLY GUIDE US? Asist. Prof. M.D. Mehmet Akif KARAMERCAN Gazi University School of Medicine Depertment of Emergency Medicine 1 NO CONFLICT OF INTEREST 2 We do not fully understand
More informationSepsis Management: Past, Present, and Future
Sepsis Management: Past, Present, and Future Benjamin Ferrell, MD Tennessee ACP Meeting October 28, 2017 Learning Objectives Identify the most updated definition and clinical criteria for sepsis Describe
More informationBIOMARKERS IN SEPSIS
BIOMARKERS IN SEPSIS Dr. Syed Ghulam Mogni Mowla Assistant Professor, Medicine, DMC BSMCON 17 WHY WE NEED TO KNOW Sepsis and its complications are a common cause of infectious disease illness and mortality
More informationSepsis: What Is It Really?
Sepsis: What Is It Really? Steven D. Burdette, MD, FIDSA, FACP Professor of Medicine Wright State University Boonshoft School of Medicine Director of Antimicrobial Stewardship for Premier Health and Miami
More informationSepsis 3 & Early Identification. Disclosures. Objectives 9/19/2016. David Carlbom, MD Medical Director, HMC Sepsis Program
Sepsis 3 & Early Identification David Carlbom, MD Medical Director, HMC Sepsis Program Disclosures I have no relevant financial relationships with a commercial interest and will not discuss off-label use
More informationInternational Journal of Advanced Research in Biological Sciences ISSN : Research Article
International Journal of Advanced Research in Biological Sciences ISSN : 2348-8069 www.ijarbs.com Research Article Serum level of IL-6, IL-10 and PCT as a prognostic marker in post traumatic sepsis patients.
More informationFluid balance and clinically relevant outcomes
Fluid balance and clinically relevant outcomes Rui Moreno, MD, PhD, Professor UCINC, Hospital de São José Centro Hospitalar de Lisboa Central, E.P.E. INSULT PRIMARY MODS SIRS SECONDARY MODS OUTCOME RECOVERY
More informationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 Mitchell M. Levy MD, MCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care
More informationEarly infection diagnosis
Procalcitonin in the EMERGENCY DEPARTMENT Early infection diagnosis and risk assessment with Procalcitonin (PCT) Early differential diagnosis and therapy decision in the emergency department Antibiotic
More informationUpdate on Sepsis Diagnosis and Management
CHAPTER 12 Update on Sepsis Diagnosis and Management Kevin Alexander, DPM INTRODUCTION Sepsis and septic shock have become a large problem in the health care system that affects at least 1 million people
More informationWhat the ED clinician needs to know about SEPSIS - 3. Anna Morgan Consultant EM Barts Health
What the ED clinician needs to know about SEPSIS - 3 Anna Morgan Consultant EM Barts Health Aims: (1) To review the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) (2)
More informationSepsis: Update on Diagnosis, Evaluation and Management
Sepsis: Epidemiology Sepsis: Update on Diagnosis, Evaluation and Management Michael J. Apostolakos, MD Professor of Medicine Director of Adult Critical Care University of Rochester ~ 750,000 cases per
More informationClinical Guide to Use of PROCALCITONIN. for Diagnosis and PCT-Guided Antibiotic Therapy
Clinical Guide to Use of PROCALCITONIN for Diagnosis and PCT-Guided Antibiotic Therapy The content of this booklet was kindly written by: Philipp Schuetz, MD, MPH Privat Dozent for Endocrinology and Internal
More informationSepsis overview. Dr. Tsang Hin Hung MBBS FHKCP FRCP
Sepsis overview Dr. Tsang Hin Hung MBBS FHKCP FRCP Epidemiology Sepsis, severe sepsis, septic shock Pathophysiology of sepsis Recent researches and advances From bench to bedside Sepsis bundle Severe sepsis
More informationL utilizzo della Procalcitonina in Medicina d Urgenza
L utilizzo della Procalcitonina in Medicina d Urgenza Stefania Battista Dirigente Medico S.C. Medicina d Urgenza Azienda Ospedaliero-Universitaria San Giovanni Battista di Torino Savona, 15 ottobre 2009
More informationSEPSIS: IT ALL BEGINS WITH INFECTION. Theresa Posani, MS, RN, ACNS-BC, CCRN M/S CNS/Sepsis Coordinator Texas Health Harris Methodist Ft.
SEPSIS: IT ALL BEGINS WITH INFECTION Theresa Posani, MS, RN, ACNS-BC, CCRN M/S CNS/Sepsis Coordinator Texas Health Harris Methodist Ft. Worth 1 2 3 OBJECTIVES Review the new Sepsis 3 definitions of sepsis
More informationUpdates in Sepsis 2017
Mortality Cases Total U.S. Population/1,000 Updates in 2017 Joshua Solomon, M.D. Associate Professor of Medicine National Jewish Health University of Colorado Denver Background New Definition of New Trials
More informationNew sepsis definition changes incidence of sepsis in the intensive care unit
New sepsis definition changes incidence of sepsis in the intensive care unit James N Fullerton, Kelly Thompson, Amith Shetty, Jonathan R Iredell, Harvey Lander, John A Myburgh and Simon Finfer on behalf
More informationEvidence-Based. Management of Severe Sepsis. What is the BP Target?
Evidence-Based Management of Severe Sepsis Michael A. Gropper, MD, PhD Professor and Vice Chair of Anesthesia Director, Critical Care Medicine Chair, Quality Improvment University of California San Francisco
More informationISF criteria (International sepsis forum consensus conference of infection in the ICU) Secondary peritonitis
Appendix with supplementary material. This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Supplementary Tables Table S1. Definitions
More information/////// Procalcitonin. Solutions for Emergency Diagnostics. A Novel Biomarker for Bacterial Infections and Sepsis. VIDAS Emergency Assays
/////// Solutions for Emergency Diagnostics 2015 BIOMÉRIEUX, INC. BIOMÉRIEUX, THE BLUE LOGO AND VIDAS ARE USED PENDING AND/OR REGISTERED TRADEMARKS BELONGING TO BIOMÉRIEUX SA OR ONE OF ITS SUBSIDIARIES
More informationClinical Diagnosis and Severity Assessment in Immunocompetent Adult Patients with Community-Acquired Pneumonia
Chapter 5 Clinical Diagnosis and Severity Assessment in Immunocompetent Adult Patients with Community-Acquired Pneumonia Fernando Peñafiel Saldías, Orlando Díaz Patiño and Pablo Aguilera Fuenzalida Additional
More informationPneumonia in the Hospitalized
Pneumonia in the Hospitalized Patient: Use of Steroids Nicolette Myers, MD Pulmonary/Sleep/Critical Care November 9, 2018 Park Nicollet Clinic Facts About Pneumonia CAP is the 8 th most common cause of
More informationEARLY GOAL DIRECTED THERAPY : seminaires iris. Etat des lieux en Daniel De Backer
EARLY GOAL DIRECTED THERAPY : Etat des lieux en 2017 Daniel De Backer Head Dept Intensive Care, CHIREC hospitals, Belgium Professor of Intensive Care, Université Libre de Bruxelles Past-President European
More informationAdsorbtion of Cytokines Early in Septic Shock: the ACESS trial
Adsorbtion of Cytokines Early in Septic Shock: the ACESS trial Prof. Zsolt Molnár zsoltmolna@gmail.com Department of Anaesthesia and Intensive Care University of Szeged Hungary Pathophysiology Local insult
More informationTeresa Cardoso 1 *, Armando Teixeira-Pinto 2, Pedro Pereira Rodrigues 3, Irene Aragão 4, Altamiro Costa- Pereira 5, António E. Sarmento 6.
Predisposition, Insult/Infection, Response and Organ Dysfunction (PIRO): A Pilot Clinical Staging System for Hospital Mortality in Patients with Infection Teresa Cardoso 1 *, Armando Teixeira-Pinto 2,
More informationSepsis or Severe Sepsis? Is there a right thing, and how do we do it?
Sepsis or Severe Sepsis? Is there a right thing, and how do we do it? Steven Q Simpson, MD, FCCP, FACP Professor of Medicine Division of Pulmonary and Critical Care University of Kansas Disclosures No
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for
More informationCELLULAR IMMUNOTHERAPY FOR SEPTIC SHOCK: CISS Phase I Trial
CELLULAR IMMUNOTHERAPY FOR SEPTIC SHOCK: CISS Phase I Trial Lauralyn McIntyre, MD, FRCPC, MHSc Associate Professor, University of Ottawa Senior Scientist, Ottawa Hospital Research Institute CCCF MEETING,
More informationInitial Resuscitation of Sepsis & Septic Shock
Initial Resuscitation of Sepsis & Septic Shock Dr. Fatema Ahmed MD (Critical Care Medicine) FCPS (Medicine) Associate professor Dept. of Critical Care Medicine BIRDEM General Hospital Is Sepsis a known
More informationPneumonia Severity Scores:
Pneumonia Severity Scores: Are they Accurate Predictors of Mortality? JILL McEWEN, MD FRCPC Clinical Professor Department of Emergency Medicine University of British Columbia Vancouver, BC Canada President,
More informationA BRIEF HISTORY OF SEPSIS. Euan Mackay
A BRIEF HISTORY OF SEPSIS Euan Mackay Aims History of sepsis definition Validity of new definition Hippocrates 4 th century BC Hippocrates introduced the term "σήψις the process of decay or decomposition
More informationBiomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study
DOI 10.1186/s13613-016-0134-8 RESEARCH Open Access Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study Pedro Póvoa 1,2*, Ignacio Martin Loeches 3,4, Paula Ramirez 4,5,
More informationUse of procalcitonin assay to streamline antibiotic usage. Dr Kristine Luk
Use of procalcitonin assay to streamline antibiotic usage Dr Kristine Luk Outline Procalcitonin physiology & kinetics Limitations Different settings - primary care & AED - critically ill patients - neutropenic
More informationLooking for sepsis. Sepsis: Update. Prevalence of High Profile Dzs. Screening and risk stratification. Mortality of High Profile Diseases
Sepsis: Update Prevalence of High Profile Dzs Edward A. Panacek, MD, MPH Professor and Chair, Emergency Medicine USA Medical Center, Mobile, AL NDAFP Conference Big Sky. 2016 Syllabus Angus Crit Care Med
More informationFluid Resuscitation and Monitoring in Sepsis. Deepa Gotur, MD, FCCP Anne Rain T. Brown, PharmD, BCPS
Fluid Resuscitation and Monitoring in Sepsis Deepa Gotur, MD, FCCP Anne Rain T. Brown, PharmD, BCPS Learning Objectives Compare and contrast fluid resuscitation strategies in septic shock Discuss available
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationJAMA. 2016;315(8): doi: /jama
JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287 SEPSIS 3 life-threatening organ dysfunction caused by a dysregulated host response to infection organ dysfunction: an increase in the SOFA
More informationEFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK. Alexandria Rydz
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK Alexandria Rydz BACKGROUND- SEPSIS Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated
More informationSURVIVING SEPSIS: Early Management Saves Lives
SURVIVING SEPSIS: Early Management Saves Lives Pat Posa RN, BSN, MSA System Performance Improvement Leader St. Joseph Mercy Health System Ann Arbor, MI Patricia.posa@stjoeshealth.org Objectives a. Understand
More informationSepsis. Current Dilemmas in Diagnosing Sepsis. Chapter 2
Chapter 2 Current Dilemmas in Diagnosing Derek Braun Derek Braun, Banner Health, 2901 N. Central Ave. Ste 180, Phoenix, AZ 85012 Email: derek.braun@bannerhealth.com Abbreviations: APACHE : Acute Physiology,
More informationSepsis and Shock States
Sepsis and Shock States Presented By: Cynthia Webner BSN, RN, CCRN, CMC www.cardionursing.com CNEA 2009 1 INFECTION Inflammatory response to microorganisms, or Invasion of normally sterile tissues SYSTEMIC
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More information5/1/2015 SEPSIS SURVIVING SEPSIS CAMPAIGN HOW TO APPROACH THE POSSIBLE SEPTIC CHILD 2015 INFECTION CAN BE CONFIRMED BY:
SURVIVING SEPSIS CAMPAIGN HOW TO APPROACH THE POSSIBLE SEPTIC CHILD 2015 Omer Nasiroglu MD Baptist Children s Hospital Pediatric Emergency Department SEPSIS IS A SYSTEMIC INFLAMMATORY RESPONSE SYNDROME
More informationWhat is sepsis? RECOGNITION. Sepsis I Know It When I See It 9/21/2017
Sepsis I Know It When I See It September 15, 2017 Matthew Exline, MD MPH Medical Director, Medical ICU What is sepsis? I shall not today attempt further to define the kinds of material [b]ut I know it
More informationThe Septic Patient. Dr Arunraj Navaratnarajah. Renal SpR Imperial College NHS Healthcare Trust
The Septic Patient Dr Arunraj Navaratnarajah Renal SpR Imperial College NHS Healthcare Trust Objectives of this session Define SIRS / sepsis / severe sepsis / septic shock Early recognition of Sepsis The
More informationAndrea Blotsky MDCM FRCPC General Internal Medicine, McGill University Thursday, October 15, 2015
The TIMES Project: (Time to Initiation of Antibiotic Therapy in Medical Patients Presenting to the Emergency Department with Sepsis) - Preliminary Findings Andrea Blotsky MDCM FRCPC General Internal Medicine,
More informationSeptic Shock. Rontgene M. Solante, MD, FPCP,FPSMID
Septic Shock Rontgene M. Solante, MD, FPCP,FPSMID Learning Objectives Identify situations wherein high or low BP are hemodynamically significant Recognize complications arising from BP emergencies Manage
More informationECMO: a breakthrough in care for respiratory failure. PD Dr. Thomas Müller Regensburg no conflict of interest
ECMO: a breakthrough in care for respiratory failure? PD Dr. Thomas Müller Regensburg no conflict of interest 1 Overview Mortality of severe ARDS Indication for ECMO PaO 2 /FiO 2 Efficiency of ECMO: gas
More informationUsing procalcitonin (PCT) to improve the odds in sepsis management
Using procalcitonin (PCT) to improve the odds in sepsis management Disclaimer This guide provides information for healthcare professionals on the optimal use of procalcitonin (PCT) testing and the subsequent
More informationManaging Patients with Sepsis
Managing Patients with Sepsis Diagnosis; Initial Resuscitation; ARRT Initiation Prof. Achim Jörres, M.D. Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum
More informationTop Sepsis Studies
A75M233/A75M529 Monday 08:00-09:15 Wednesday 14:45-16:00 Maureen A Seckel APRN, ACNS-BC, CCRN, CCNS, FCCM Critical Care CNS and Sepsis Leader Christiana Care Health Services, Newark, DE Top Sepsis Studies
More informationUPDATE IN HOSPITAL MEDICINE
UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some
More informationDetecting and Removing Endotoxin in sepsis
Toronto 2015 Detecting and Removing Endotoxin in sepsis Claudio Ronco, MD Department of Nephrology Dialysis and Transplantation International Renal Research Institute San Bortolo Hospital Vicenza Italy
More informationStability in community-acquired pneumonia: one step forward with markers?
1 Servicio de Neumología. Universitary Hospital La Fe, Ciber de enfermedades respiratorias (CIBERES),Valencia, Spain; 2 Servicio de Infecciosas, Hospital Clinic, IDIBAPS, Barcelona, Spain; 3 Servicio de
More informationBasics from anatomy and physiology classes Local tissue reactions
Septicaemia & SIRS Septicaemia is a life-threatening condition that arises when the physical reaction to an infection, causes damage to tissue and organs Basics from anatomy and physiology classes Local
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationSurviving Sepsis Campaign Guidelines 2012 & Update for David E. Tannehill, DO Critical Care Medicine Mercy Hospital St.
Surviving Sepsis Campaign Guidelines 2012 & Update for 2015 David E. Tannehill, DO Critical Care Medicine Mercy Hospital St. Louis Be appropriately aggressive the longer one delays aggressive metabolic
More informationSepsis. From EMS to ER to ICU. What we need to be doing
Sepsis From EMS to ER to ICU What we need to be doing NEHAL BHATT, MD ATHENS PULMONARY, CRITICAL CARE AND SLEEP Objectives 1. Define the changes to the definition of Sepsis 2. Describe the assessment,
More informationSepsis Update: Focus on Early Recognition and Intervention. Disclosures
Sepsis Update: Focus on Early Recognition and Intervention Jessie Roske, MD October 2017 Disclosures I have no actual or potential conflict of interest in relation to this program/presentation. I will
More informationPortugal. From SACiUCI to InfAUCI. Sepsis epidemiology: an update. You re only given a little spark of madness. You mustn t lose it.
Sepsis epidemiology: an update Portugal João Gonçalves Pereira ICU director Vila Franca Xira Hospital From SACiUCI to InfAUCI You re only given a little spark of madness. You mustn t lose it. Robin Williams
More informationSepsis: Identification and Management in an Acute Care Setting
Sepsis: Identification and Management in an Acute Care Setting Dr. Barbara M. Mills DNP Director Rapid Response Team/ Code Resuscitation Stony Brook University Medical Center SEPSIS LECTURE NPA 2018 OBJECTIVES
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationSepsis and Septic Shock: New Definitions for Adults
PL Detail-Document #320424 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2016 Sepsis and Septic
More informationUpdates in Emergency Department Management of Sepsis
Resident Journal Review Updates in Emergency Department Management of Sepsis Authors: Eli Brown, MD; Allison Regan, MD; Kaycie Corburn, MD; Jacqueline Shibata, MD Edited by: Jay Khadpe, MD FAAEM; Michael
More information3 papers from ED. counting sepsis sepsis 3 wet or dry?
3 papers from ED counting sepsis sepsis 3 wet or dry? 5 million deaths/yr globally 24 billion USD annually in US system causes or contributes to half of US hospital deaths BP GCS RR From: The Third International
More informationa new biomarker in sepsis management Lunch Symposium, ISICEM 2016
a new biomarker in sepsis management Lunch Symposium, ISICEM 2016 Heparin-Binding Protein - an early marker of sepsisinduced organ dysfunction Dr Adam Linder, Lund, Sweden Elevated plasma Heparin Binding
More informationIntravenous Vitamin C. Severe Sepsis Acute Lung Injury
Intravenous Vitamin C Severe Sepsis Acute Lung Injury Alpha A. (Berry) Fowler, III, MD Professor of Medicine VCU Pulmonary Disease and Critical Care Medicine I Have No Disclosures Bacterial Sepsis Approximately
More information